Ischemic heart disease has one of the leading places among the important problems of contemporary cardiology. The
currently used approaches to assessment of complications risk and to determine of appropriate preventive and curative measures
are not always perfect and specific. At present, the hospital uses a large number of biochemical markers of myocardial infarction
prognosis (troponins, creatine phosphokinase, C-reactive protein (CRP), Nt-proBNP, and others.), were suggested a lot of prognostic
models, however, as have appeared the new markers of prognostic model, providing for the use of multiple indicators to assess the
risk, creates the potential for further improvement of diagnosis and clinical outcome of patients with myocardial infarction. New
perspective and widely studied marker is galectin-3. This review discusses the diagnostic and prognostic value of this biomarker in
patients with both acute and chronic heart failure, as well as approaches to the various therapeutic effects on the level of galectin-3.

1. Ageev F.T., Azizova A.G. Galectin-3 – a new biochemicalmarker of heart failure // Heart failure. 2011.Vol. 12, № 2. P. 108-114.
2. Bobrovskaya E.E., Burova N.N., Cohn V.E. Predictorsof complicated course and poor prognosis in patients withmyocardial infarction // Arterial hypertension. 2009.Vol. 15, № 5. P. 539-542.
3. Bogova O.T., Chukaeva I.I. Myocardial infarction.Inflammation and prognosis // Russian Journal of Cardiology.– 2003. № 4. P. 95-98.
4. Vasilieva O.A., Yakusheva V.D., Ryazantseva N.V.,Novitsky V.V. Possibilities of use of galectin-3 in laboratorydiagnostics // Scientific and Practical Journal «Clinical andLaboratory Concilium». 2011. № 2. P. 12-18.
5. Vashakidze Z.S., Tseluyko V.I., Bregvadze T.R. Galectin-3 - a new biomarker for heart failure, inflammation andfibrosis // Heart failure. 2011. № 3. P. 73-76.
6. Voloshin N.A., Grigorieva E.A. Lectins of animal andvegetable origin, the role in the morphogenesis // TeoretycnaMedycyna «Journal of AMS of Ukraine». 2005.Vol. 11, № 2. P. 223-237.
7. Dubolazova Yu.V. Evaluation of the clinical courseof chronic heart failure with preserved ejection fraction:Abstract. Dis. ... Cand. Med. Sci. M., 2012. 29 p.
8. Zykov M.V., Kashtalap V.V., Zykova D.S., KaretnikovaV.N., Tavlueva E.V., Kolomytseva I.S., Barbarash O.L. Predictionof myocardial infarction complications within one yearof observation // Siberian Journal of Medicine. 2011 –Vol. 26, № 4. P. 41-46.
9. Mit’kovskaya N.P., Nizhnikova O.G., Statkevich T.V.,Pateyuk I.V., Balysh E.M., Pinchuk A.F. Pathogenetic aspectsof post-infarction remodeling // Medical Journal. 2013.№ 1 (43). P. 12-18.
10. Nechesova T.A., Korobko I. Yu., Kuznetsova N.I. Leftventricular remodeling: pathogenesis and evaluation methods// Medical News. 2008. № 11. P. 7-13.
11. Snetkova A.A., Timofeeva N.Yu, Zadionchenko V.S.Diagnostic value of galectin-3 in patients with chronic heartfailure and type 2 diabetes mellitus // Rational pharmacotherapyin cardiology. 2015. № 11. P. 139-143.
12. Sulimov V.A. Contemporary methods of diagnosing thearrhythmias // Heart. 2002. № 2. P. 65-71.
13. Sumarokov A.B. Risk-stratification of patients withcoronary heart disease // Russian Medical Journal.1999. Vol. 6, № 14. P. 896-905.
14. Usol’tseva E.N., Barbarash O.L. Location of brainnatriuretic peptide in predicting of the course of acute coronarysyndrome // Pathology of the circulatory and cardiacsurgery. 2010. № 4. P. 74-78.
15. Tseluyko V.I., Lozovaya T.A. Galectin-3 and the stateof post-infarction remodeling in patients with right ventricularmyocardial infarction on the background of the left ventricularposterior wall infarction // Ukrainian Journal of Cardiology.– 2014. № 5. P. 37-43.
16. Shakhnovich R.M. Markers of inflammation, NtproBNPand infectious factor in patients with acute coronarysyndrome and its significance for determining thedisease outcome prognosis: Abstract. Dis. ... Dr. Med. Sci.M., 2011. 44 p.
17. Anand I.S., Rector T.S. Kuskowski M., Adourian A.,Muntendam P, Cohn J.N. Baseline and serial measurements ofgalectin-3 in patients with heart failure: relationship to prognosisand effect of treatment with valsartan in the Val-HeFT// Eur. J. Heart Fail. 2013. Vol. 15, № 5. P. 511-518.
18. Bax J. J., van der Wall, Harbinson M. Radionuclidetechniques for the assessment of myocardial viability andhibernation // Heart.2004. Vol. 90. P. 26-30.
19. Biasucci L.M., Liuzzo G., Grillo R.L., Caliqiuri G.,Rebuzzi A.G., Buffon A., Summaria F., Ginnetti F., Fadda G.,Maseri A. Elevated levels of C-reactive protein at dischargein patients with unstable angina predict recurrent instability// Circulation. 1999. Vol. 99. P. 855-860.
20. Calvier L., Martinez-Martinez E., Miana M., CachofeiroV., Rousseau E., Sádaba J.R., Zannad F., Rossignol P., López-Andrés N. The impact of galectin-3 inhibition on aldosteroneinducedcardiac and renal injuries // JACC Heart Fail.2015. Vol. 3, № 1. P.59-67.
21. Calvier L., Miana M., Reboul P., Cachofeiro V.,Martinez E., R. de Boer et al. Galectin-3 mediates aldosterone-Induced Vascular Fibrosis // Arterioscler. Thromb.Vasc. Biol. 2013. № 33.P. 67-75.
22. De Boer R.A., Yu L., van Veldhuisen D.J., Galectin-3in cardiac remodeling and heart failure // Curr. HeartFail. Rep. 2010. Vol. 7, № 1. P. 1-8.
23. De Boer R.A., van Veldhuisen D.J., Gansevoort R.T.,Muller Kobold A.C., van Gilst W.H., Hillege H.L., BakkerS.J., van der Harst P. The fibrosis marker galectin-3 andoutcome in general population // J. Intern. Med. 2012.Vol. 272. P. 55-64.
24. De Lemos J. A., Peacock W. F., McCullough P. A. Natriureticpeptides in the prognosis and management of acutecoronary syndromes // Rev. Cardiovasc. Med. 2010.Vol. 11, № 2. P. 24-34.16 Сибирское медицинское обозрение, 2016, 125. Erkilet G., Ozpeker C., Bothing D., Kramer F., RofeD., Bohms B., Morshuits M., Gummert J., Milting H. Thebiomarker plasma galectin-3 in advanced heart failureand survival with mechanical circulatory support devices// J. Heart Lung Transplant. 2013. Vol. 32, № 2.P. 211-230.
26. Fiuzat M., Schulte P.J., Felker M., Ahmad T., NeelyM., Adams K.F., Donahue M.P., Kraus W.E., Piña I.L., WhellanD.J., O’Connor C.M. Relationship between galectin-3levels and mineralocorticoid receptor antagonist use in heartfailure: analysis from HF-ACTION // J. Card. Fail. 2014.Vol. 20, № 1. P. 38-44.
27. Fukumori T., Takenaka Y., Yoshii T., Kim H.R., HoganV., Inohara H., Kagawa S., Raz A. CD29 and CD7 mediategalectin-3-induced type II T-cell apoptosis // Cancer Res.2003. Vol. 63. P. 8302-8311.
28. George M., Shanmugam E., Srivatsan V., VasanthK., Ramraj B., Rajaram M., Jena A., Sridhar A., ChaudhuryM. Value of pentraxin-3 and galectin-3 in acute coronarysyndrome: a short-term prospective cohort study // Ther.Adv. Cardiovasc. Dis. 2015. Vol. 9, № 5. Р. 275-284.
29. Grandin E. Wilson, Petr Jarolim, Sabina A. Murphy,Lea Ritterova, Christopher P. Cannon, Eugene Braunwaldand David A. Morrow.Galectin-3 and the developmentof HF after Acute Coronary Syndrome: pilot experiencefrom PROVE IT-TIMI 22 // Clinical Chemistry. 2011.Vol. 58, № 1. P. 1-7.
30. Gullestad L., Ueland T., Kjekshus J., Nymo S. H.,Hulthe J., Muntendam P., Adourian A., Bohm M., D.J. vanVeldhuisen, Komajda M. Galectin-3 predicts response to statintherapy in the Controlled Rosuvastatin Multinational Trialin Heart Failure (CORONA) // European Heart Journal.2012. Vol. 33. P. 2290-2296.
31. Heeschen C., Hamm C. W., Mitrovic V., Lantelme N.H.,White H.D. N-terminal pro-B-type natriuretic peptide levelsfor dynamic risk stratification of patients with acute coronarysyndromes // Circulation. 2004. Vol. 110. P. 3206-3212.
32. Henderson N.C., Mackinnon A.C., Farnworth S.L.,Kipari T., Haslett C., Iredale J.P., Liu F.T., Hughes J., SethiT. Galectin-3 expression and secretion links macrophages tothe promotion of renal fibrosis // Am. J. Pathol. 2008.Vol. 172, № 2. P. 288-298.
33. Iwata M., Cowling R.T., Yeo S.J., Greenberg B. Targetingthe Ace2–Ang-(1–7) pathway in cardiac fibroblaststo treat cardiac remodeling and heart failure // Journal OfMolecular And Cellular Cardiology. 2011. Vol. 51,Iss. 4. P. 542-547.
34. James S.K., Armstrong P., Barnatan E., Callif R., LindahlB., Siegbahn A., Simoons M.L., Topol E.J., Venge P., WallentinL. Troponin and C-reactive protein have different relationsto subsequent mortality and myocardial infarction afteracute coronary syndrome: a GUSTO-IV substudy // J. Am.Coll. Cardiol. 2003. Vol. 41. P. 916-924.
35. James S.K., Lindahl B., Siegbahn A., Stridsberg M.,Venge P., Armstrong P., Barrathan E.S., Califf R., Topol E.J.,Simoons M.L, Wallentin L. N-terminal pro-brain natriureticpeptide and other risk markers for the separate prediction ofmortality and subsequent myocardial infarction in patientswith unstable coronary artery disease: a Global Utilization ofStrategies To open occluded arteries (GUSTO) – IV substudy// Circulation. 2003. Vol. 108. P. 275-281.
36. Januzzi J.L., Camargo C.A., Anwaruddin S., Bagish A.L.,Chen A.A., Krauser D.G., Tung R., Cameron R., Naqurney J.T.,Chae C.U., Lloyd-Jones D.M., Brown D.F., Foran-MelansonS., Sluss P.M., Lee-Lewandrowski E., Lewandrowski K.B. TheN-terminal proBNP investigation of dyspnea in the emergencydepartment (PRIDE) study // Am. J. Cardiol. 2005.Vol. 95, № 8. P. 948-954.
37. Jennifer E. Ho, Chunyu Liu, AsyaLyass, PaulCourchesne, Michael J. Pencina, Ramachandran S. Vasan,Martin G. Larson, Daniel Levy. Galectin-3, a Marker of CardiacFibrosis, Predicts Incident Heart Failure in the Community// Journal of the American College of Cardiology. 2012.Vol. 60, № 14. P. 1249-1256.
38. Lax A., Sanchez-Mas J., Asensio-Lopez M. C., Fernandez-Del Palacio M. J., Caballero L., Garrido I. P., Pastor-PerezF. J., Januzzi J. L., Domingo A. Mineralocorticoid ReceptorAntagonists Modulate Galectin-3 and Interleukin-33/ST2Signaling in Left Ventricular Systolic Dysfunction AfterAcute Myocardial Infarction // JACC Heart Fail. 2015.№ 3. P. 50-58.
39. Lindahl B., Toss H., Siegbahn A., Venge P., WallentinL. Markers of myocardial damage and inflammation in relationto long-term mortality in unstable coronary disease. FRISCsubstudy group. Fragmin during Instability in Coronaryartery disease // N. Engl. J. Med. 2000. Vol. 343.P. 1139-1147.
40. Liu Y.H., D’Ambrosio M., Liao T.D., Peng H., RhalebN.E., Sharma U., Andreu S., Gabius H.J., Carretero O.A.N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodelingand dysfunction induced by galectin-3, a mammalianadhesion growth-regulatory lectin // Am. J. Physiol.Heart. Circ. Physiol. 2009. Vol. 296.P. 404-412.
41. Lok D.J., Van Der Meer P., de la Porte P.W., Lipsic E.,Van Wijngaarden J., Hillege H.L., van Veldhuisen D.J. Prognosticvalue of galectin-3, a novel marker of fibrosis, in patientswith chronic heart failure: data from the DEAL-HF study// Clin. Res. Cardiol. 2010. Vol. 99, №5. P. 323-328.
42. Lopez-Andres N., Rossignol P., Iraqi W., Fay R., NueeJ., Chio S., Cleland J.G., Zannad F., Lacolley P. Associationof galectin-3 and fibrosis markers with long-term cardiovascularoutcomes in patients with heart failure, left ventriculardysfunction and dyssynchrony: insights from CARE-HFtrial // Eur. J. Heart Fail. 2012. Vol. 14. P. 74-81.
43. Mallick A., Januzzi J.L. Biomarkers in acute heartfailure // Rev. Esp. Cardiol. 2015. Vol. 68. P. 514-525.Перспективы использования галектина-3 как маркера неблагоприятного прогноза у пациентов с инфарктом миокарда с подъемом сегмента ST 1744. Mandelzweig L., Battler A., Boyko V., Bueno H.,Danchin N., Filippatos G., Gitt A., Hasdai D., Hasin Y., MarrugatJ., Van de Werf F., Wallentin L., Behar S. The second EuroHeart Survey on acute coronary syndromes: characteristics,treatment, and outcome of patients with ACS in Europe andthe Mediterranean Basin in 2004 // Eur. Heart. J. 2006.Vol. 27. P. 2285-2293.
45. Martinez E., Lopez-Andres N., Jurado-Lopez R., RousseauE., Bartolome M.V., Fernandez-Celis A., Rossignol P.,Islas F., Antequera A., Prieto S., Luaces M., Cachofeiro V. Galectin-3 participates in cardiovascular remodeling associatedwith obesity // Hypertension. 2015. Vol. 66. P. 961-969.
46. Memon L., Spasojevic-Kalimanovska V., Bogavac-Stanojevic N., Kalimanovska-Ostric D., Jelic-Ivanovic Z., SpasicS., Topic A. Association of C-reactive protein with the Presenseand Extent of Angiographically Verified Coronary Artery Disease// J. Exp. Med. 2006. Vol. 209. Р. 197-206.
47. Nishi Y., Sano H., Kawashima T., Okada T., Kuroda T.,Kikkawa K., Kawashima S., Tanabe M., Goto T., MatsuzawaY., Matsumura R., Tomioka H., Liu F.T., Shirai K. Role ofgalectin-3 in human pulmonary fibrosis // Allergol. Int.2007. Vol. 56. P 57-65.
48. O’Connor C.M., Whellan D.J., Lee K.L., KeteyianS.J., et. al. Efficacy and safety of exercise training in patientswith chronic heart failure: HF-ACTION randomized controlledtrial // JAMA. 2009. Vol. 8, № 301(14). Р. 1439-1450.
49. Ochieng J. Furtak V., Lukyanov P. Extracellularfunctions of galectin-3 // Glycoconj J. 2004. Vol. 19.P. 527-535.
50. Omland T., Persson A., Nq L., O’Brien R., Karlsson T.,Herlitz J., Hartford M., Caidahl K. N-terminal pro-B-type natriureticpeptide and long-term mortality in acute coronary syndromes// Circulation. 2002. Vol. 106. P. 2913-2918.
51. Sharma U.C., Pokharel S., van Brakel T.J., van Berloj.H., Cleutjens J.P., Shroen B., Andre S., Crijns H.J., GabiusH.J., Maessen J., Pinto Y.M. Galectin-3 marks activated macrophagesin failure-prone hypertrophied hearts and contributesto cardiac dysfunction // Circulation. 2004. Vol. 110,№ 19. P. 3121-3128.
52. Sharma U., Rhaleb N.E., Pokharel S., Harding P.,Rasoul S., Peng H., Carretero O.A. Novel anti-inflammatorymechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertensioninducedtarget organ damage // Am. J. Physiol. Heart Circ.Physiol. 2008. Vol. 294, № 3. P. 1226-1232.
53. Tsai T.H., Sung P.H., Chang L.T., Sun C.K., Yeh K.H.,Chung S.Y., Chua S., Chen Y.L., Wu C.J., Chang H.W., KoS.F., Yip H.K. Value and level of galectin-3 in acute myocardialinfarction patients undergoing primary percutaneous coronaryintervention // Journal of Atherosclerosis and thrombosis.2012. Vol. 19. P. 1073-1082.
54. Van der Velde A. R., L.Gullestad, T. Ueland, P.Aukrust,Y. Guo, A. Adourian, P. Muntendam, D. J. van Veldhuisenand R. A. de Boer. Prognostic Value of Changes in Galectin-3Levels Over Time in Patients With Heart Failure: Data FromCORONA and COACH // Circ. Heart Fail. 2013.Vol. 6. P. 219-226.
55. Van Kimmenade R.R., Januzzi J.L. Jr, Ellinor P.T.,Sharma U.C., Bakker J.A., Low A.F., Martinez A., Crijns H.J.,MacRae C.A., Menheere P.P., Pinto Y.M. Utility of aminoterminalpro-brain natriuretic peptide, galectin-3, and apelinfor the evaluation of patients with acute heart failure // J. Am.Coll. Cardiol. 2006. Vol. 48, № 6. P. 1217-1224.
56. WHO. The top 10 causes of death. Fact sheet N 310,updated May 2014. [Электронный ресурс]. Режимдоступа: http://www.who.int/mediacentre/factsheets/fs310/en/index.html57. Widimsky P., Wijns W., Fajadet J, de Belder M, KnotJ. Reperfusion therapy for ST elevation acute myocardial infarctionin Europe: description of the current situation in 30countries // Eur. Heart. J. 2010. Vol. 31. P. 943-957.
58. Willerson J.T., Ridker P.M. Inflammation as a cardiovascularrisk factor // Circulation. 2004. Vol. 109.P. 110-112.
59. Yang R.Y., Rabinovich G.A., Li F.T. Galectins: structure,function and therapeutic potential // Expert. Rev. Mol.Med. 2008. Vol. 13. P. 17-39.
60. Yu L., Ruifrok W.P., Meissner M., Bos E.M. Geneticand pharmacological inhibition of galectin-3 prevents cardiacremodeling by interfering with myocardial fibrogenesis// Circ. Heart Failure. 2013. Vol. 6, № 1. P. 107-117.

This article presents scientific overview, related to the problem of cognitive impairments seen in patients with stroke.
It was discussed the structure of post-stroke cognitive disorders, diagnostic capabilities, including in non-Russian nationalities,
relevance of prevention and treatment, issues of cognitive rehabilitation.

1. Vakhnina N.V., Nikitina L.Yu, Parfenov V.A.Poststroke cognitive impairments // Journal of Neurologyand Psychiatry named after S.S. Korsakov. 2008.App. «Stroke». Vol. 22. P. 16-21.
2. Verbitskaya S.V., Parfenov V.A. Clinical experienceof memantine use at poststroke dementia // NeurologyJournal. 2008. № 4. P.45-48.
3. Grigorieva V.N., Nesterova V.N. Cognitiverehabilitation of patients with focal lesions of the brain// Practical Medicine. 2012. № 2. P. 70-74.
4. Damulin I.V. Vascular mild cognitive impairments// Psychiatry and psycho-pharmacotherapy. 2005.№ 5. P. 295-299.
5. Zakharov V.V., Vakhnina N.V. Stroke andcognitive impairments // Neurology, Neuropsychiatry,Psychosomatics. 2011. № 2. P. 8-16.
6. Klimov L.V., Parfenov V.A. Cognitive impairmentsin acute ischemic stroke // Journal of Neurology.2006. № 1. P. 53-57.
7. Levin O.S. Diagnosis and treatment of dementia inclinical practice. M .: MEDpress-Inform, 2010. 256 p.
8. Levin O.S., Dudarova M.A., Usol’tseva N.I. Diagnosisand treatment of poststroke cognitive impairments// Consilium Medicum. 2010. № 2. P. 5-12.
9. Levin O.S., Damulin I.V. Diffuse changes of whitematter (leykoareoz) and the problem of vascular dementia// Advances in Neurogeriatrics. M.: MMA, 1995.Part 2. P. 189-231.
10. Levin O.S., Sagova M.M., Golubeva L.V. Factorsinfluencing on factors of life of the patients with circulatoryencephalopathy with mild cognitive impairment // RussianMedical Journal. 2006. № 3. P. 25-28.
11. Luria A.R. Higher cortical functions of man.SPb. : Peter, 2007. 624 p.
12. Prokopenko S.V., Mozheyko E.Yu., Koryagina T.D.Features of cognitive training using specialized computerprograms in post-stroke patients // Journal of Neurology.– 2014. № 1. P. 20-24.
13. Khrakovskaya M.G. Optimization of neuropsychologicalrehabilitation strategies on the example of therecovery of visual gnosis // Materials of the I InternationalCongress «Neurorehabilitation 2009», June 2-3, 2009.M., 2009. P.
48.
14. Yahno N.N., Preobrazhenskaya I.S., Zakharov V.V.et al. Efficacy of akatinol memantine in patients with nondementia cognitive impairments. Results of the multicenterclinical observation // Journal of Neurology. 2010.№ 2. P. 52-58.
15. Yahno N.N. Cognitive disorders in the neurologicalclinic // Journal of Neurology. 2006. App. № 1.P. 4-12.
16. Barker-Collo S. L., Feigin V. L., Lawes C. M., Parag V.,Senior H., Rodgers A. Reducing attention deficits after strokeusing attention process training: a randomized controlledtrial // Stroke. 2009. Vol. 40, № 10. P. 3293-3298.
17. Bezdenezhnykh A., Prokopenko S., Mozheyko E.Computer cognitive training and entertaining games forcognitive rehabilitation of post stroke patients // ICVD2015 Abstract CD 9th International Congress on VascularDementia.-Ljubljana, ICVD 2015 Abstract CD. 2015.
18. Borson S., Scanlan, J., Brush, M., Vitallano, P.,&Dokmak, A. (2000). The Mini-Cog: A cognitive ‘vital signs’measure for dementia screening in multi-lingual elderly// International Journal of Geriatric Psychiatry. 2000.Vol. 15, № 11. Р. 1021-1027.
19. Braun S., Kleynen M., Schols J., Schack T., BeurskensA., Wade D. Using mental practice in stroke rehabilitation:a framework // Clin. Rehabil. 2008. Vol. 22, № 7.P. 579-591.
20. Cogmed Working Memory Training [Electronicresourse]. URL: http://www.cogmed.com/. (Дата об-ращения: 22.03.2016).
21. CogniFit [Electronic resourse]. URL: https://www.cognifit.com/ru. (Дата обращения: 22.03.2016).
22. Corrada M. M., Brookmeyer R., Paganini-Hill A.,Berlau D., Kawas CH. Dementia incidence continues toincrease with age in the oldest old // Ann. Neurol.2010. Vol. 67. P. 114-121.
23. Craig D., Birks J. Galantamine for vascular cognitiveimpairment [Electronic resourse] // D. Cochrane DatabaseSyst. Rev. 2006. Vol. 25, № 1. CD004746.
24. Craig D., Birks J. Rivastigmine for vascular cognitiveimpairment [Electronic resourse] // D. Cochrane DatabaseSyst. Rev. 2005. №2. CD004744.
25. Danovska M., Stamenov B., Alexandrova M.,Peychinska D. Poststroke cognitive impairment –phenomenology and prognostic factors // J. IMAB.2012. Vol. 18, № 3. P. 290-297.
26. Davies P. The cholinergic deficit in Alzheimer’sdisease P. Davies // Alzheimer’s disease: 100 years andbeyond / eds. M. Jucker, K. Beyreuther, C. Haass. Berlin,Heidelberg : Springer-Verlag, 2006. P. 123-125.
27. Feldman H. H., Jacova C., Robillard A., GarciaA., Chow T., Borrie M., Schipper H., Blair M., KerteszA., Chertkow H. Diagnosis and treatment of dementia:2. Diagnosis // Can. Med. Assoc. J. 2008. Vol. 178,№ 7. P. 825-836.
28. Ginarte-Arias Y. Cognitive rehabilitation. Theoreticaland methodological aspects // Rev. Neurol. 2002.Vol. 35, № 9. Р. 870-876.
29. Hachinski V. C., Lassen M. A., Marshall J. Multiinfarctdementia. A case of mental deterioration in the elderly// Lancet. 1974. Vol. 2, № 7874. P. 207-210.
30. Happy Neuron [Electronic resourse]. URL: http://www.happyneuron–corp.com/en.(Дата обращения:22.03.2016).
31. Kalaria R. N., Lewis H., Cookson N. J., ShearmanM. The impact of cerebrovascular disease on Alzheimer’spathology in elderly // Neurobiol. Aging. 2000.Vol. 21, № 1. P. 66-67.
32. Kennelly S. P., Lawlor B. A., Kenny R. A. Bloodpressure and the risk for dementia: adoubleed ged sword// Ageing Res. Rev. 2009. Vol. 8, № 2. P. 61-70.
33. Klingberg T., Fernell E., Olesen P. J., Johnson M.,Gustafsson P., Dahlstrom K., Gillberg C.G., Forssberg H.,Westerberg H. Computerized training of working memoryin children with ADHD – a controlled, randomized, doubleblindtrial // J. Am. Acad. Child. Adolesc. Psychiatry.2005. Vol. 44, № 2. P. 177-186.
34. Launer L. J., Masaki K., Petrovich H., Foley D., HavlikR. J. The association between midlife blood pressure levelsand late–life cognitive function. The Honolulu–AsiaAging Study // JAMA. 1995. Vol. 274, № 23.P. 1846-1851.
35. Launer L. J., Ross G. W., Petrovik H., Masaki K.,Foley D., White L. R. Midlife blood pressure and dementia:the Honolulu-Asia aging study // Neurobiol. Aging.2000. Vol. 21, № 1. P. 49-55.
36. Leys D., Неnon H., Mackowiak-Cordoliani M. A.,Pasquier F. Poststroke dementia // Lancet. Neurol. 2005.Vol. 4, № 11. Р. 752-759.
37. Liman T. G., Heuschmann P. U., Endres M., Flöel A.,Schwab S., Kolominsky-Rabas P. L. Changes in cognitivefunction over 3 years after first–ever stroke and predictors ofcognitive impairment and long-term cognitive stability: theErlangen Stroke Project // Dement. Geriatr. Cogn. Disord.2011. Vol. 31, № 4. P. 291-299.
38. Lin H.J., Wolf P.A., Beiser A.S., Kelly-Hayes M., KaseC. S., Au R., White R. Insidence of dementia after stroke:the Framingham study // Neurology. 1997. Vol. 48,№ 3. Suppl. 2. P. A283.
39. Logroscino G. J., Kang H., Grodstein F. Prospectivestudy of type 2 diabetes and cognitive decline in womenaged 70–81 years // Br. Med. J. 2004. Vol. 328,№ 7439. P.548.
40. Lumosity [Electronic resourse]. URL: http://www.lumosity.com/. (Дата обращения: 22.03.2016).
41. McNab F., Varrone A., Farde L., Jucaite A., BystritskyP., Forssberg H., Klingberg T. Changes in cortical dopamineD1 receptor binding associated with cognitive training// Science. 2009. Vol. 323, № 5915. Р. 800-802.
42. McShane R., Areosa-Sastre A., Minakaran N.Memantine for dementia [Electronic resourse] CochraneDatabaseSyst. Rev. 2006; 4. CD003154.
43. Mindspark [Electronic resourse]. URL: http://www.mindspark.com/. (Дата обращения: 22.03.2016).
44. Miotto E. C., Serrao V. T., Guerra G. B., Souza deLúcia G., Mara C., Scaff M. Cognitive rehabilitation ofneuropsychological deficits and mild cognitive impairment// Dementia neuropsychol. 2008. Vol. 2, № 2.Р. 139-145.
45. Narasimhalu K., Effendy S., Sim C. H., Lee J. M.,Chen I., Hia S. B., Xue H. L., Corrales M. P., Chang H. M.,Wong M. C., Chen C. P., Tan E. K. A randomized controlledtrial of rivastigmine in patients with cognitive impairment nodementia because of cerebrovascular disease // Acta Neurol.Scand. 2010. Vol. 121, № 4. P. 217-224.
46. Narasimhalu K., Ang S., De Silva D. A., H.-m. Theprognostic effects of poststroke cognitive impairment nodementia and domain–specific cognitive impairments innondisabled ischemic stroke patients // Stroke. 2011.Vol. 42, №4. P. 883-888.
47. Olesen P. J., Westerberg H., Klingberg T. Increasedprefrontal and parietal activity after training of workingmemory // Nat. Neurosci. 2004. Vol. 7, № 1.P. 75-79.
48. Pendlebury S. T., Rothwell P. M. Prevalence,incidence, and factors associated with pre–stroke andpost-stroke dementia: a systematic review and meta-analysis// Lancet. Neurol. 2009. ol. 8, № 11. P.1006-1018.
49. Petersen R. S., Smith G. E., Waring S. C., Ivnik R. J.,Tangalos E. G., Kokmen E. Mild cognitive impairment:clinical characterization and outcome // Arch. Neurol.1999. Vol. 56, № 3. P. 303-308.
50. Petersen R. C. Mild cognitive impairment as adiagnostic entity // J. Intern. Med. 2004. V. 256,№ 3. Р. 183-194.
51. Posit Science [Electronic resourse]. URL: http://www.positscience.com/. (Дата обращения: 22.03.2016).
52. Prigatano G. P. Frequency and clinical determinantsPrinci ples of neuropsychological rehabilitation // OxfordUniuersity Press. 2002. P. 25-42.
53. Rasquin S. M., Lodder J., Pondas R. W., Winkens I.,Jolles J., Verhey F. R. Cognitive functioning after stroke:a one-year follow-up study // Dement. Geriatr. Cogn.Disord. 2004. Vol 18, № 2. Р. 134-144.
54. Snowdon D. A., Greiner L., Mortimer J., Riley K. P.,Greiner Р. Brain infarction and the clinical expression ofAlzheimer’s disease. The Nun Study // JAMA. 1997.Vol. 277, № 10. P. 813-817.
55. Sohlberg M. M., Mateer C. A. Cognitive Rehabilitation:An integrative neuropsychological approach. New York:Guilford Press, 2001. 246 p.
56. Westerberg H., Jacobaeus H., Hirvikoski T.,Clevberger P., Ostensson M. L., Bartfai A., Klingberg T.Computerized working memory training after stroke – apilot study // Brain Inj. 2007. Vol. 21, № 1. P. 21-29.
57. Xu Q., Lin Y., Geng J. L., Li H. W., Chen Y., Li Y. S.The prevalence and risk factors for cognitive impairmentfollowing ischemic stroke // Zhonghua Nei Ke Za Zhi.2008. Vol. 47, № 12. P. 981-984.
58. Ylvisaker M., Jacobs H. E., Feeney T. Positivesupports for people who experience behavioral and cognitivedisability after brain injury: a review // J. Head TraumaRehabil. 2003. Vol. 18, № 1. P. 7-32.

The review includes the information on the state of reproductive health of female students with the deficit of body mass.
It is discussed the role of fat mass deficit in the reproductive health, bioimpedance metric indicators.

1. Andreyeva V.O. The role of leptin and neuropeptide Yin the pathogenesis of reproductive disorders in adolescentgirls with anorexia nervosa // Vestnik VolgSMU. 2009.№ 4. P. 84-87.
2. Andreyeva V.O. Pathogenetically proved method ofdifferential diagnosis of disorders of menstrual function inadolescent girls with body mass deficit // Russian Vestnikof Obstetrician-gynecologist. 2008. Vol. 8, № 3.P. 62-66.
3. Blinova E.G., Akimova I.S., Chesnokova M.G.,Demakova L.V. Results of the analysis of anthropometricand bioempidansometric researches in students of Omsk// Contemporary problems of science and education.2014. № 3. P. 19-21.
4. Boboeva H.G. The gestation process in women with bodymass deficit // SCI-ARTICLE.RU. 2014. № 16. P. 12-14.
5. WHO: Memorandum of the meeting convened byUSAID, WHO, PAHO and organization aimed to assist mothers(«Mother Care»). The use of anthropometry in women to predictpregnancy outcomes // WHO Bulletin. 1997. Vol. 69,№ 5. P. 11-21.
6. WHO Coordinators Meeting on the problems of safeguardthe health of women and children: a report of the meeting. -Geneva: WHO Regional Office for Europe, 2009. 22 p.
7. Vikhlyaeva E.M. Manual on Endocrine Gynecology.M.: OOO «Medical News Agency», 2006. 784 p.
8. Gasymova U.R., Sosnova E.A. Changes in the functionalstate of the ovaries in women of reproductive age afterorgan-preserving surgical procedures on the pelvic organs// Obstetrics and Gynecology named after V.F. Snegirev.2014. № 2. P. 32-35.
9. Goncharova S.V., Bashmakova N.V. Preclinical diagnosisof ovarian reserve in adolescent girls with intrauterinehypotrophy // Clinical Laboratory Diagnostics. 2008.№ 9. P. 5-6.
10. Denisova T.G., Vasilieva E.N., Gruzinova E.N. Theetiology and pathogenesis of disorders of the reproductivesystem in women with deficit of body mass (review) // Healthof Chuvashia. 2014. № 1. P. 10-15.
11. Dodkhoeva M.F., Ismailova Z.M., Khodzhaeva F.H.Miscarriage in women with deficit of body mass // Reports ofthe Academy of Sciences of the Republic of Tajikistan. Medicineand Health care. 2007. Vol. 50, № 6. P. 551-553.
12. Dmitrieva E.V. The media and their impact onthe reproductive behavior of young people in Russia// Reproductive health of children and adolescents. 2006.– № 4. P. 34-38.
13. Egorycheva E.V., Musina S.V. The study of body weightdeviations in current students // Contemporary studies of socialproblems. 2011. Vol. 8, № 4. P. 57-61.
14. Enikeev B.V., Gaidukov S.N. Creating the informationmodel of assessment the pregnancy and childbirth in womenwith deficit of body mass. // Bulletin of Academy of Pediatrics.– 2006. №. 4. P. 114-118.
15. Ioffe L.A. Features of puberty in urban and ruraladolescent girls // Hygiene and sanitation. 2003.№ 1. P.53-54.
16. Kolycheva S.S., Kutumova S.L. Dynamics of physicaldevelopment of medical students in 40 years // Successes ofmodern science. 2006. № 1. P. 87-88.
17. Kadochnikova N.I. Status of menstrual function, levelof somatic and reproductive health of girls 17-19 years old withvarying menstrual cycles // Medical Almanac. 2008.№ 5. P. 89-92.
18. Kulakov V.I. Reproductive health: challenges,achievements and prospects // Problems of reproduction.1999. № 2. P. 6-7.
19. Kulikov A.M., Crotin P.N., Panova O.V. The participationof the pediatrician in the care of reproductive health of childrenand adolescents // Farmateka. 2011. № 6. P. 8-13.
20. Crotin P.N., Yuriev V.K., Kulikov A.M. The reproductivepotential of contemporary teenage girls // Gedeon Richterin the CIS. 2001. № 3. P. 5-8.
21. Kurbatova A.V., Egorova A.T., Sindeeva L.V. Indicatorsof anthropometric survey of teenage girls and girls of Taimyr// Siberian Medical Review. 2010. № 6. P.41-43.
22. Loseva T.A., Golubkina N.A., Rachkova V.P. Physicaland mental health of the first-year student // Vocationaleducation. Set. 2011. № 8. P. 46-47.
23. Martirosov E.G., Nikolaev D.V., Rudnev S.G. Thetechnologies and methods of determining the compositionof the human body. M.: “Nauka” of RAS, 2006. 246 p.
24. Martynova A.G., Kodochigova A.I., Kirichuk V.F.The role of the psycho-physiological and anthropometriccharacteristics in the occurrence of psychosomatic pathology:lack of body mass - a risk factor // Saratov Journal of MedicalScience. 2007. № 3 (17). P. 25-28.
25. Mishkova T.A., Negasheva M.A. Characteristics ofphysical development of students of Moscow State University16-18 years old. M., 2002. Dep. VINITI №1010-V2002.
26. Nikolaev V.G., Sindeeva L.V., Nekhaeva T.I., YusupovR.D. The composition of the human body: history of researchand new technologies of definition // Siberian MedicalReview. 2011. № 2. P. 3-7.
27. Nikolaev V.G., Medvedeva N.N., Sindeeva L.V.,Derevtsova S.N. Biophysical markers and their role in assessingof human physical status // Siberian Medical Review.2013. № 6. P.30-33.
28. Ozerskaya I.A., Pykov M.I., Zabolotskaya N.V.Sonography of the reproductive system of a girl, a teenage girl,maiden. M.: Vidar, 2012. 32 p.
29. Peshkov M.V., Sharaikina E.P. Indicators of studentsbody mass: current state of problem // Siberian MedicalReview. 2014. № 4. P. 35-39.
30. The Order of Ministry of Health RF № 114 dated 21.03.03“On approval of the branch program “Protection and Improvementof the Healthy Health for 2003-2010.“ – Moscow, 200331. Radzinsky V.E. Female adolescents RF: moderntendencies of formation of reproductive potential (review)// Siberian Journal of Medicine. 2010. Vol. 25, № 4.Issue 2. P. 9-14.
32. Sivokhina T.A. The impact of risk factors on thereproductive function of girls // Vestnik of SSU: science,technology series. 2007. № 8 (58). P. 252-259.
33. Ushakova G.A., Rudaeva E.V. Regulatory adaptationprocesses in the mother-placenta-fetus in women with deficitof body mass // Siberian Journal of Medicine. 2007.№ 1. P.78-80.
34. Hamoshina M.B., Abdullayeva R.G., Khaskhanova L.S.Features of formation the menstrual functions in teenagegirls with the deficit of body mass // Bulletin of PFUR. Series«Medicine. Obstetrics and gynecology». 2009. № 5.P. 116-122.
35. Khuraseva A.B. Features of mineral metabolism in girlsdepending on birthweight and approaches to prevention andtreatment of disorders of mineral metabolism // Archives ofInternal Medicine. 2011. № 1. P 64-66.
36. Shilova O.Yu. Features of physical and sexualdevelopment of adolescent girls in modern conditions// Siberian bulletin of special education. 2015. № 2.P. 120-124.
37. Yakimovich V.S., Egorycheva E.V. The relationship ofhealth and physical fitness indicators of the student youth withdeficit of body mass // Scientific notes of the University namedafter P.F. Lesgaft. 2012. № 5. P. 173-177.
38. Yashchuk A.G. The formation of the reproductive systemof adolescent girls in modern conditions // Reproductive healthof children and adolescents. 2012. № 6. P. 30-44.
39. Chen B., Lu Y.N., Wang H.X. Sexual and reproductivehealth service needs of university/college students: updatesfrom a survey in Shanghai, China // Asian J. Androl.2008. Vol. 10, № 4. P. 607-615.
40. Dittmar M. Reliability and variability of bioimpedancemeasures in normal adults: effects of age, gender, and bodymass // Am. J. Phys. Anthropol. 2003. Vol. 122, № 4.P. 361-370.
41. Ege E., Akin B., Kultiir R. The attitudes towards andbehaviours about sexual and reproductive health in universitystudents // Ibid. 2008. Vol. 13, Suppl. 2. P. 70.
42. Elguina S.I., Ouchakova G.A. Reproductive potential ofgirls - teenages of nowadays in Kemerovo // Eur. J. Contracep.Reprod. Health Care. 2002. Vol. 7, Suppl. l. P. 69.
43. Gavin L., MacKay A.P., Brown K. Sexual andreproductive health of persons aged 10-24 years, UnitedStates, 2002-2007 // MMWR Surveill Summ. 2009. Vol. 6,№ 58. P. 1-58.
44.Gallagher D., Heymsfield S.B., Heo M. Healthypercentage body fat ranges: an approach for developingguidelines based on body mass index // Am. J. Clin. Nutr.2000. Vol. 72, № 3. P. 694-701.
45. Gazdzinski S., Durazzo T.C., Mon A., Meyerhoff D.J.Body mass index is associated with brain metabolite levels inalcohol dependence a multimodal magnetic resonance study// Alcohol Clin. Exp Res. 2010. Vol. 34, № 12.P. 2089-2096.
46. Heymsfield S.B., Gallagher D., Mayer L. Scaling of humanbody composition to stature: new insights into body mass index// Am. J. Clin. Nutr. 2007. Vol.86, №1. P. 82-91.
47. Ward L.C. Segmental bioelectrical impedance analysis:an update // Curr. Opin. Clin. Nutr. Metab. Care. 2012.Vol. 15, № 5. P. 424-429.
49.Ward L.C. Bioelectrical impedance validation studies:alternative approaches to their interpretation // Eur. J. Clin.Nutr. 2013. Vol. 67, № 1. P. 10-13.

The article is devoted to the questions of individual approach in organizing and conducting the nutritional
support in the perioperative period in patients with malignant tumors of gastro - intestinal tract. Here presented the
review of current data on the principles of personalization of diagnostic and therapeutic technologies of the contemporary
nutrition in oncology.

1. Hirsch A.O, Mal’kov O.A., Khorova E. Yu., KurakinV.I. Informativity of separate indicators of nutritionalstatus in oncological surgical patients // Omsk ScientificBulletin. 2012. 2 (114). P. 103-106.
2. Zavertaylo L.L., Mal’kov O.A., Leiderman I.N.Technology of metabolic monitoring and selection ofnutritional support program in patient at critical condition// Intensive therapy.2007. № 1. P. 65-77.
3. Kuz’mina T.N., Sil’vestrova S.Yu., KostyuchenkoL.N., Ruchkina I.N., Petrakov A.V. The metabolicactivity of the intestinal microflora and its role indetermining the tactics of nutritional support in the remoteperiod after gastrectomy // Experimental and clinicalgastroenterology. 2009. № 6. P. 35-44.
4. Kutukov V.V., Idieva U.K., Ivanov R.B., ShchitkaV.A. Perioperative nutritional support in operations onthe stomach // Medical science and education of theUrals. 2012. № 2. P. 41-45.
5. Leiderman I.N., Snegovoy A.V., Khlynov I.B.Chikunova M.V., Lisovskaya T.V. Basic principles andclinical nutrition technologies in oncology: a guidefor physicians. M., 2006. 36 p.
6. Leiderman I.N., Malkova O.G., Levit A.L., LevitD.A., Prudkov M.I. Protocols and algorithms for nutritionalsupport in surgical clinic // Vestnik of Ural MedicalAcademic Science. 2009. № 3. P. 89-91.
7. Luft V.M., Luft A.V. Clinical aspects of nutritionalsupport for patients in medicine: an ideology, opportunities,standards // Russian Medical Journal. 2009.№ 5. P. 8-14.
8. Makeeva T.K., Galkin A.A. Trophological status ofpatients with gastric cancer // Vestnik Saint - PetersburgUniversity. 2008. series 11 (1). P. 105-117.
9. Mal’kov O.A., Moroz V.V., Dolgikh V.T. Nutritionalsupport in oncological surgery // General Reanimatology.– 2008. № 2. P.94-97.
10. Obukhova O.A., Kishin Sh.R., Sviridova S.P.Strategy of perioperative nutritional support in surgicalpatients // Consilium – medicum. 2010. Vol. 12,№ 38. P. 97 -103.
11. Obukhova O.A. Kurmukov I.A., Kashiyastr Sh.R.The nutritional support in oncology // Oncogynecology.– 2014. № 1. P. 34 - 45.
12. Basics of nutritional support in the oncologicalclinic / Ed. Member – correspondent of RAMSA.I. Saltanov. M., 2009. 239 p.
13. Pasechnik I.N., Gubaidullin R.R., Borisov A.Yu.The basics of nutritional support of patients in criticalconditions. M.: Coliseum, 2012. 160 p.
14. Popova T.S., Shestopalov A.E., Protsenko D.N.The practice of nutritional support in the intensive caredepartments of the Russian Federation // Journal ofAnesthesiology and Intensive Care. 2011. Vol. 8,№ 5. P. 7-10.
15. Pugaev A.V., Achkasov E.E. Assessment ofnutritional status and identifying the need for nutritionalsupport: a tutorial. M.: Profile, 2007. 103 p.
16. Guide on Clinical Nutrition / Ed. Luft V.M.,Bagnenko S,F., Shcherbuka Yu.A. SPb. 2010.P. 74-102.
17. Parenteral and Enteral Nutrition Guide / Ed. I.E.Khoroshilova. Normed, 2000. P. 63-73.
18. Snegovoy A.V., Leiderman I.N., Saltanov A.I.,Sel’chuk V.Yu. Basic Principles and Clinical Nutritiontechnologies in oncology: a guide for physicians.M., 2009. 38 p.
19. Snegovoy A.V., Saltanov A.I., Manzyuk L.V.,Sel’chuk V.Yu. Nutritional deficiency in cancer patients:Principles of correction // Russian Medical Journal.2013. № 1. P. 14-21.
20. Khalikova E.Yu. Personalisation of parenteralnutrition in surgical oncology practice // The difficultpatient. 2014. № 6. P. 25-31.
21. Khubutiy M.Sh., Popova T.S., Saltanov A.I.Parenteral and enteral nutrition: national guide.M.: GEOTAR - Media, 2014 – 800 p.
22. August D.A., Huhmann M.B. American Societyfor Parenteral and Enteral Nutrition (ASPEN) Board ofDirectors. ASPEN clinical guidelines: nutrition supporttherapy during adult anticancer treatment and inhematopoietic cell transplantation // JPEN. 2009.Vol. 33, № 5. P. 472-507.
23. Baldwin C., Spiro A., Ahern R., Emery P. W. Oralnutritional interventions in malnourished patients withcancer: a systematic review and meta-analysis // J. Natl.Cancer Inst. 2012. Vol. 104, № 5. P. 371-385.
24. Bistrian B.R. Brief history of parenteral and enteralnutrition in the hospital in the USA // Nestle Nutr.Workshop Ser Clin. Perform Programme. 2009.Vol. 12. P. 127-136.
25. Bozzetti F., Arends J., Lundholm K., MicklewrightA., Zurcher G, Muscaritoli M. ESPEN Guidelines onParenteral Nutrition: Non - surgical oncology // ClinicalNutrition. 2009. Vol. 28. P. 445-454.
26. Grigoraş I./ Fast-trach surgery – a new concept –the perioperative anesthetic management // Jurnalul deChirurgie, Iasi. 2007. Vol. 3, № 2. P. 89-91.
27. Human body composition - 2nd Edition / ed.by Steven B. Heymsfield , T. Lohman, Zi-M. Wang,S. Going. H.: Human Kinetics Publishers, 2005.536 p.
28. Jie B., Jiang Z. M., Nolan M. T., Zhu S.N., YuK., Kondrup J. Impact of preoperative nutritional supporton clinical outcome in abdominal surgical patientsat nutritional risk. // Nutrition. 2012. Vol. 28,№ 10. P. 1022-1027.
29. Kyle U.G., Bosaeus I., De Lorenzo A.D. et al.Bioelectrical impedance analysis - part I: review ofprinciples and methods // Clin. Nutr.2004.Vol. 23, № 5. P. 1226-1243.
30. Santarpia L., Contaldo F., Pasanisi F. Nutritionalscreening and early treatment of malnutrition in cancerpatients // J. Cachexia Sarcopenia Muscle. 2011.Vol. 2, № 1. P. 27-35.
31. Singer P., Anbar R., Cohen J., Shapiro H., Shalita- Chesner M., Lev S., Grozovski E., Theilla M., FrishmanS., Madar Z. The tight calorie control study (TICACOS):a prospective, randomized, controlled pilot study ofnutritional support in critically ill patients // Inten.Care Med. 2011. Vol. 37, № 4. P. 601-609.
32. Wichmann M.W., Roth M., Jauch K.W., Bruns C.J.A prospective clinical study for multimodal „fasttrack”rehabilitation in elective pancreatic cancer surgery// Rozhl. Chir. 2006. Vol. 85, № 4. Р. 169-175.
33. Yamamoto T., Nakahigashi M., Umegae S. Enteralnutrition for the maintenance of remission in Crohn’sdisease: a systematic review// Eur. J. Gastroenterol.Hepatol. 2010. Vol. 22, № 1. P. 1-8.
34. Zaloga G.P. Parenteral nutrition in adult inpatientswith functioning gastrointestinal tracts: assessment ofoutcomes // Lancet. 2006. Vol. 367. P. 1101-1111.

The article presents the conditions of the appearance spread of new psychoactive substances, provides
the main factors influencing to changes in the demand and consumption of potentially dangerous new psychoactive
substances, shows the changes and the consequences that touches the narcological service.

1. Analysis of activity at day and night stay hospitalKGBUZ «Krasnoyarsk Regional Narcological Dispensary№ 1» for 2012-2014 // Archive KGBUZ KKND, 2015.21 p.
2. Analysis of activity day and night stay hospitalKGBUZ «Krasnoyarsk Regional Drug Dispensary №1»in 2008-2010 // Archive KGBUZ KKND, 2011. 19 p.
3. Veselovskaya N.V., Kovalenko A.E. Drugs - properties,action, pharmacokinetics, metabolism. M.: Triad-X, 2000. 204 p.
4. Report of the International Narcotics Control Boardfor 2013 / International Narcotics Control. New York:United Nations, 2014. 128 p.
5. The results of the activities of the Federal Serviceof the Russian Federation for Drug Control in the firsthalf of 2015 [Electronic resource] // Access mode: http://www.fskn.gov.ru/pages/main/prevent/3939/4052/index.shtml (Request date 16.
10. 2015).
6. Kaklyugin N.V. «Synthetic» Russia: progressivesuicide of narcotizing youth. Problems and prospects// Medicine. 2014. № 4. P. 1-27.
7. Kataev S.S., Krylova E.A., Zelenina N.B., KurdinaL.N. Identification of metilendioksipirovalerona and itsmetabolites in urine by GC-MS // Problems of expertexamination in medicine. 2010. № 3-4. P. 32-35.
8. Koshkina E.A., Shamota A.Z., Kirzhanova V.V. Thestudy of the dynamics of prevalence of drug addiction inview of the structure of consumed drugs at the regionallevel: the analyt. overview. Moscow: Russian Ministryof Health, Narcology NSC, 2002. 32 p.
9. Koshkina E.A., Kirzhanova V.V., Guseva O.I.,Grigorova N.I., Mugantseva L.A. Providing drug treatmentto the population of the Russian Federation in 2012// Problems of Narcology. 2013. № 4. P. 3-18.
10. Latov Yu.V. Criminal economic globalization.Part I. Contraband - a leading international criminal area[Electronic resource] // Journal «The economic theory ofcrime and punishment.» – № 5-1. Access mode: http://corruption.rsuh.ru/magazine/5-1/n5-15.html (Requestdate 25/04/2015).
11. Latov Yu.V. Economy beyond the law: essays on thetheory and history of the shadow economy. M.: MoscowPublic Science Foundation, 2001. 280 p.
12. About adopting the list of narcotic drugs, psychotropicsubstances and their precursors, subjected to control inthe Russian Federation: Government Resolution № 681 dd.30 June, 1998 (02.07.2015 Ed.) [Electronic resource] // SPS«KonsultanPlyus». Access mode: http://base.consultant.ru/cons/cgi/online.cgi?req=doc;base=LAW;n=182573(Request date 17/10/2015).
13. Ovchinnikov A.A., Patrikeeva O.N. Synthetic cannabinoids:psychotropic effects, side effects, the risks ofuse [Electronic resource] // Health and education in Siberia.– 2014 – No. 3. Access mode: http://www.ngmu.ru/cozo/mos/article/text_full.php?id=1431 (Requestdate 09/16/2015).
14. The table of main indicators of operational activityin units as compared to the ATS units in the period01.01.2015-30.09.2015 // Archive UFSKN Russia for theKrasnoyarsk Territory, 2015 – 5 p.
15. The table of main indicators of operationalactivity in units as compared to the ATS units in theperiod 01.01.2012-31.
12.2012 // Archive UFSKN Russia forthe Krasnoyarsk Territory, 2013 – 3 p.
16. The table of main indicators of operational activityin units as compared to the ATS units in the period01.01.2013-31.
12.2013 // Archive UFSKN Russia for theKrasnoyarsk Territory, 2014 – 5 p.
17. The table of main indicators of operational activityin units as compared to the ATS units in the period01.01.2014-31.
12.2014 // Archive UFSKN Russia for theKrasnoyarsk Territory, 2015 – 5 p.
18. The table of main indicators of operational activityin units as compared to the ATS units in the period01.01.2014-30.09.2014 // Archive UFSKN Russia for theKrasnoyarsk Region, 2014 – 5 p.
19. Fedorov A.V., Fedulov A.V. The first InternationalConvention on the Control of Narcotics Drugs.2007. № 4. P. 37-44.
20. Tselinsky B.P. Designer drugs: about legislativeand normative-legal regulation of combating withillicit trafficking of narcotic drugs analogs and psychotropicsubstances // Narkonet. 2011. № 9.P. 18-24.
21. Compton D.R., Rice K.C., De Costa B.R., RazdanR.K., Melvin L.S., Johnson M.R., Martin B.R. Cannabinoidstructure-activity relationships: correlation of receptorbinding and in vivo activities // J. Pharmacol. Exp.Ther. 1993. Vol. 265, № 1. P. 218-226.
22. De Vry J., Jentzsch K. R. Discriminative stimuluseffects of BAY 38-7271, a novel cannabinoid receptoragonist // Eur. J. Pharmacol. 2002. Vol. 457,№ 2-3. P. 147-152.
23. Donald Hurst. Psychosis Associated With SyntheticCannabinoid Agonists: A Case Series // American Journalof Psychiatry. 2011. № 168. С. 1119-1119.
24. Economic and social council. Statistical Commission,Thirty-fifth session, 2-5 March 2004. Item 3 of theprovisional agenda. Demographic and social statistics:statistics of drugs and drug use [Electronic resource].URL : http://unstats.un.org/unsd/statcom/doc04/2004-l1e.pdf (дата обращения 25.04.2015).
25. EMCDDA-Europol Joint Report on a new psychoactivesubstance: MDPV (3,4-methylenedioxypyrovalerone)[Electronic resource]. Lisbon : EMCDDAEuropol,2014. URL: http://www.emcdda.europa.eu/publications/joint-report/MDPV (дата обращения06.05.2015).
26. Karlsson L., Andersson M., Kronstrand R., KugelbergF.C. Mephedrone, methylone and 3,4-methylenedioxypyrovalerone(MDPV) induce conditionedplace preference in Mice // Basic Clin. Pharmacol.Toxicol. 2014. Vol. 115, Iss. 5. P. 411-416.
27. Mauler F., Mittendorf J., Horváth E., De VryJ. Characterization of the diarylether sulfonylester(-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoidreceptor agonist with neuroprotective properties// J. Pharmacol. Exp. Ther. 2002. Vol. 302, № 1.P. 359-368.
28. Recommended methods for the identification andanalysis of cannabis and cannabis products (Revisedand updated). Manual for use by national drug analysislaboratories. Laboratory and Scientific Section United NationsOffice on Drugs and Crime, Vienna. N. Y.: Unitednations, 2009. 60 p.
29. Schneir A., Ly B.T., Casagrande K., Darracq M.,Offerman S.R., Thornton S., Smollin C., Vohra R., RangunC., Tomaszewski C., Gerona R. R. Comprehensive analysisof «bath salts» purchased from California stores andthe internet // Clin. Toxicol. (Phila). 2014. Vol. 52,№ 7. P. 651-658.
30. Seely K.A., Patton A.L., Moran C.L., Womack M.L.,Prather P.L., Fantegrossi W.E., Radominska-Pandya A.,Endres G.W., Channell K.B., Smith N.H., McCain K.R.,James L.P., Moran J.H. Forensic investigation of K2, Spice,and «bath salt» commercial preparations: a three-yearstudy of new designer drug products containing syntheticcannabinoid, stimulant, and hallucinogenic compounds// Forensic. Sci. Int. 2013. Vol. 233, № 1-3. P. 416-422.
31. Simmons J.R., Skinner C.G., Williams J., KangC.S., Schwartz M.D., Wills B.K. Intoxication from smoking«spice» // Ann. Emerg. Med. 2011. Vol. 57,№ 2. P. 187-188.
32. Simolka K., Lindigkeit R., Schiebel H.M., Papke U.,Ernst L., Beuerle T. Analysis of synthetic cannabinoids in«spice-like» herbal highs: snapshot of the German marketin summer 2011 // Anal. Bioanal. Chem. 2012.Vol. 404, № 1. P. 157-171.
33. Susanna Every-Palmer Synthetic cannabinoidJWH-018 and psychosis: an explorative study // Drug andAlcohol Dependence. 2011. № 117. С. 152-157.
34. The cannabis problem: A note on the problem andthe history of international action [Electronic resource]// Bulletin on Narcotics. 1962. URL : http://www.unodc.org/unodc/en/data-and-analysis/bulletin/bulletin_1962-01-01_4_page005.html (дата обращения25.04.2015).
35. Thornton S.L., Lo J., Clark R.F., Wu A.H., GeronaR.R. Simultaneous detection of multiple designer drugsin serum, urine, and CSF in a patient with prolongedpsychosis // Informa. 2012. № 10. С. 1165-1168.
36. Uchiyama N., Kawamura M., Kikura-Hanajiri R.,Goda Y. Identification and quantitation of two cannabimimeticphenylacetylindoles JWH-251 and JWH-250,and four cannabimimetic naphthoylindoles JWH-081,JWH-015, JWH-200, and JWH-073 as designer drugs inillegal products // Forensic Toxicol. 2011. Vol. 29,№ 1. P. 25-37.
37. Uchiyama N., Kikura-Hanajiri R., Kawahara N.,Haishima Y., Goda Y. Identification of a cannabinoidanalog as a new type of designer drug in a herbal product// Chem. Pharmaceutical Bulletin (Tokyo). 2009.Vol. 57, № 4. P. 439-441.
38. Van der Veer N., Friday J. Persistent psychosisfollowing the use of Spice // Schizophr. Res. 2011.Vol. 130, № 1–3. P. 285-286.
39. Watterson L.R., Kufahl P.R., Nemirovsky N.E.,Sewalia K., Grabenauer M., Thomas B.F., Marusich J.A.,Wegner S., Olive M.F. Potent rewarding and reinforcingeffects of the synthetic cathinone 3,4-methylenedioxypyrovalerone(MDPV) // Addict. Biol. 2014. Vol. 19,Iss. 2. P. 165-174.
40. Weissman A., Milne G.M., Melvin L.S. Jr. Cannabimimeticactivity from CP-47,497, a derivative of 3-phenylcyclohexanol// J. Pharmacol. Exp. Ther. 1982.Vol. 223, № 2. P. 516-523.
41. World Drug Report 2015 [Electronic resource].United Nations Office on Drugs and Crime, Vienna,2015 – URL: http://www.unodc.org/documents/wdr2015/World_Drug_Report_2015.pdf (датаобращения 25.
10.2015).

The aim of the research. Assessing the role of chronic obstructive pulmonary disease in the formation of negative annual
infarction prognosis with ST-segment elevation.
Materials and methods. The study included 529 patients with STEMI, which developed during the 24 hours prior to admission
to the hospital, with no age restrictions. Hospital mortality was 10.9% (58 cases). At discharged patients were evaluated
endpoints at one year from myocardial infarction (MI): death, recurrent myocardial infarction, acute ischemic stroke,
progressive stenocardia, decompensated chronic heart failure, repeated urgent coronary revascularization, the occurrence
of which was regarded as an unfavorable annual forecast.
Results. The annual forecast is estimated at 384 people. It was found that the presence of COPD increases the risk of adverse annual
forecast of 1.9 times (95% CI 1,1-3,6, p = 0.0429), the risk of heart failure decompensation during the year by 2.6 times (95%
CI, 1,3-5,4, p = 0.0060). By the method of multivariate logistic regression were identified the predictors, significantly affecting to
the implementation of the negative annual forecast of STEMI, among which, along with the number of diseased by coronary arteries,
level of NTproBNP, BMI index included the presence in a patient with myocardial infarction accompanying COPD.
Conclusion. Chronic obstructive pulmonary disease is an independent predictor of poor prognosis, which should be considered
in risk stratification of patients with STEMI.

1. Behar S., Panosh A., Reicher-Reiss H., Zion M.,Schlesinger Z., Goldbourt U. Prevalence and prognosisof chronic obstructive pulmonary disease among 5,839consecutive patients with acute myocardial infarction.SPRINT Study Group // Am. J. Med. 1992.Vol. 93. P. 637-641.
2. Boschetto P., Beghe B., Fabbri L.M., Ceconi C. Linkbetween chronic obstructive pulmonary disease andcoronary artery disease: implication for clinical practice// Respirology. 2012. Vol. 17, № 3. P. 422-431.
3. Bursi F., Vassallo R., Weston S.A., Killian J.M.,Roger V.L. Chronic obstructive pulmonary diseaseafter myocardial infarction in the community // Am.Heart J. 2010. Vol. 160, № l. P. 95-101.
4. Hadi H.A., Zubaid M., Al Mahmeed W., El-MenyarA.A., Ridha M., Alsheikh-Ali A.A., Singh R., Assad N.,Al Habib K., Al Suwaidi J. Prevalence and prognosisof chronic obstructive pulmonary disease among 8167Middle Eastern patients with acute coronary syndrome// Clin. Cardiol. 2010. Vol. 33, № 4.P. 228-235.
5. Halkin A., Singh M., Nikolsky E., Grines C.L., TchengJ.E., Garcia E., Cox D.A., Turco M., Stuckey T.D., Na Y.,Lansky A.J., Gersh B.J., O’Neill W.W., Mehran R., StoneG.W. Prediction of mortality after primary percutaneouscoronary intervention for acute myocardial infarction: theCADILLAC risk score // J. Am. Coll. Cardiol. 2005.Vol. 45, № 9. P. 1397-1405.
6. Hawkins N.M., Huang Z., Pieper K.S., SolomonS.D., Kober L., Velazquez E.J., Swedberg K., PfefferM.A., McMurray J.J., Maggioni A.P. Chronic obstructivepulmonary disease is an independent predictor of deathbut not atherosclerotic events in patients with myocardialinfarction: analysis of the Valsartan in Acute MyocardialInfarction Trial (VALIANT) // European Journal of HeartFailure. 2009. Vol 11. P. 292-298.
7. Khan S.Q., Narayan H., Ng K.H., Dhillon O.S., KellyD., Quinn P., Squire I.B., Davies J.E., Ng L.L. N-terminalpro B type natriuretic peptide complements the GRACErisk score in predicting early and late mortality followingacute coronary syndrome // Clin. Sci. (Lond.).2009. Vol. 117, № 1. P. 31-39.
8. Kjoller E., Kober L., Iversen K., Torp-Pedersen C.Importance of chronic obstructive pulmonary diseasefor prognosis and diagnosis of congestive heart failure inpatients with acute myocardial infarction // Eur. J. HeartFail. 2004. Vol. 6. P. 71-77.
9. Lazzeri C., Valente S., Attana P., Chiostri M.,Picariello C., Gensini G.F. The prognostic role of chronicobstructive pulmonary disease in ST-elevation myocardialinfarction after primary angioplasty // Eur. J. Prev.Cardiol. 2013. Vol. 20, № 3. P. 392-398.
10. Mueller C., Breidthardt T., Laule-Kilian K., ChristM., Perruchoud A.P. The integration of BNP and NTproBNPinto clinical medicine // Swiss. Med. Wkly.2007. Vol. 137. P. 4-12.
11. Oreopoulos A., McAlister F.A., Kalantar-ZadehK., Padwal R., Ezekowitz J.A., Sharma A.M., KovesdyC.P., Fonarow G.C., Norris C.M. The relationshipbetween body mass index, treatment, and mortality inpatients with established coronary artery disease: a reportfrom APPROACH // Eur. Heart J. 2009. Vol. 30,№ 21. Р. 2584-2592.
12. Salisbury A., Reid K., Spertus J. Impact of chronicobstructive pulmonary disease on post-myocardial infarctionoutcomes // Am. J. Cardiol. 2007. Vol. 99.P. 231-23913. Schols A.M., Broekhuizen R., Weling-ScheepersC.A., Wouters E.F. Body composition and mortality inchronic obstructive pulmonary disease // Am. J. Clin.Nutr. 2005. Vol. 82. P. 53-59.
14. Taylor A.W., Price K., Gill T.K., Adams R., PilkingtonR., Carrangis N., Shi Z., Wilson D. Multimorbidity – notjust an older person’s issue. Results from an Australianbiomedical study // BMC Public Health. 2010.Vol. 10. P. 718.
15. Uretsky S., Supariwala A., Singh P., Atluri P.,Khokhar S.S., Koppuravuri H.K., Joshi R., Mandeva A.,Rozanski A. Impact of weight on long-term survival amongpatients without known coronary artery disease and anormal stress SPECT MPI // J. Nucl.Cardiol. 2010.Vol. 17, № 3. Р. 390-397.

The aim of the research. To determine risk factors for pneumonia and evaluate their significance in patients with
thoracoabdominal injuries.
Materials and methods. It was done the retrospective analysis of the results of treatment 184 patients aged 36,9 ± 8,5
years with thoracoabdominal injuries to determine the frequency and risk factors for pneumonia.
Results. It was established that the frequency of pneumonia was 19.6%. It was determined that the risk of pneumonia
depended on the severity of the injury (ISS scale), of mechanical lungs ventilation longer than 48 hours, enteral nutrition,
period of stay in a department of anesthesiology and intensive care for more than three days, two or more additional
surgical interventions. There were identified variants of antibiotic resistance of nosocomial pneumonia.
Conclusion. Were identified risk factors for pneumonia in patients with thoracoabdominal injuries.

1. Gritsan A.I., Dovbysh N.Yu., Gazenkampf A.A., Gritsan G.V. The comparison of severity of the condition,parameters of respiratory biomechanics and gas exchangein patients with stroke in the development of early andlate ventilator-associated pneumonia // Bulletin ofAnesthesiology and Reanimatology. 2013. № 4.P. 26-33.
2. Gritsan A.I., Dovbysh N.Yu., Gazenkampf A.A.,Gritsan G.V., Kurtz E.M. Risk factors, microbial landscapeand the effectiveness of antibiotic therapy in the treatmentof ventilator-associated pneumonia in patients with stroke// Journal of anesthesiology and reanimatology.2014. № 4. P. 18-293. Kolkin Ya.G., Pershin E.S., Vegner D.V.,Peschanskiy R. E. Diagnosis and surgical treatmentof thoracoabdominal trauma // Ukrainian Journalof Surgery. 2010. № 1. P. 18-20.
4. Korolev V.M. Epidemiological aspects of combinedtrauma // Far East Medical Journal. 2011. № 3.P. 124-128.
5. Maxin A. A., Valyka E.N. Tactical aspects ofdiagnosis and surgical treatment of patients withthoracoabdominal trauma // Vestnik of new medicaltechnologies. 2009. № 2. P. 190-191.
6. Nosocomial pneumonia in adults. Russian nationalguidelines // Journal of anesthesiology and reanimatology.– 2009.Vol. 6, № 5. P. 39-59.
7. Samokhvalov I.M., Nedomolkin S.V., Gavrilin S.V.,Meshakov D.P., Suvorov V.V., Smirnov S.A., FukalyakV.I. Features of reanimotological care to the patients withmultiple injuries at extremely high predicted mortality// Journal of anesthesiology and reanimatology.2014. №5. P. 20-26.
8. Sorokin E.P., Mal’chikov A.Ya., Gritsan A.I.,Voronchihin A.E., Shilyaeva E.V. Social Portrait ofpatients with combined trauma // Polytrauma. 2014.№ 1. P. 15-28.
9. Shabanov A.K., Khubutia M. Sh., Bulava G.V.,Beloborodova N.V., Kuzovlev A.N., GrebenchikovO.A., Kosolapov D.A., Shpitonkov M.I. Dynamics ofprocalcitonin level in the development of nosocomialpneumonia in patients with severe combined trauma// General Reanimatology. 2013. № 9 (5).P. 11-17.
10. Giamberardino H., Schelmezer B., Adamante H. Z.,Betum T. Pneumonia in trauma patients // AntimicrobialResistance and Infection Control. 2015. Vol. 4. P. 98.
11. Keut H., Faverio P., Restrepo M. I. Prevention ofventilator-associated pneumonia in the intensive care unit:A review of the clinically relevant recent advancements// Indian Journal of Medical Research. 2014.Vol. 139. P. 814-821.
12. Lausevic Z., Lausevic M., Trbojevic-Stankovic J.,Krstic S., Stojimirovic B. Predicting multiple organ failurein patients with severe trauma // Canadian Journal ofSurgery. 2008. Vol. 51, № 2. P. 97-102.
13. Luyt C. E., Chastre J., Fagon J. Y. Value of theClinical Pulmonary Infection Score for the identificationand management of ventilator-associated pneumonia// Intensive Care Medicine. 2004. Vol.
30. P. 844-852.
14. O’Horo J. C., Kashyap R., Herasevich V.,Sampathkumar P. The Clinical Pulmonary Infection ScoreAnd Ventilator Associated Events // American Journalof Respiratory and Critical Care Medicine. 2014.Vol. 189. P. 4563

The aim of the research. Analysis of the experience of hardware intraoperative reinfusion (IAR) in a regional
perinatal center from a position of safety and efficacy.
Materials and methods. Were subjected to a retrospective analysis 47 IAR procedures. The need for donor
transfusion environments, the frequency of multiple organ failure, the need for renal replacement therapy were
assessed.
Results. The use of IAR in patients of obstetric profile in acute massive blood loss made possible to limit the
need for allogeneic red blood cells not more than 29% of all cases of massive blood loss. IAR safety is proved by
cases of amniotic embolism and transfusion complications.
Conclusion. Undoubted clinical effect in the group IAR was achieved by preventing the development of multiple
organ failure, reducing the incidence of ARDS and the need for renal replacement therapy.

1. Fedorova T.A., Rogachevskiy O.V. Blood savingtechnologies in obstetric practice // Modern medical technology.– 2009. № 2. P. 59-62.
2. Fedorova T.A., Strelnikova E.V., Rogachevskiy O.V.,Danilov A.Yu. The use of intraoperative reinfusion autoerythrocytesin obstetric practice // Obstetrics and Gynecology.– 2010. № 4. P. 23-27.
3. Allam J, Cox M, Yentis SM. Cell salvage in obstetrics// Int. J. Obstet. Anesth. 2008. № 17. С. 37-45.
4. Blajchman M.A., Vamvakas E.C. The continuing riskof transfusion-transmitted infections // N. Engl. J. Med.2006. № 355. Р. 1303-1305.
5. Brearton C., Bhalla A., Mallaiah S., Barclay P. The economicbenefits of cell salvage in obstetric haemorrhage // Int.J. Obstet. Anesth. 2012. № 21. Р. 329-333.
6. Geoghegan J., Daniels J.P., Moore P.A.S., ThompsonP.J., Khan K.S., Gülmezoglu A.M. Cell salvage at caesareansection: the need for an evidence-based approach // BJOG: AnInternational Journal of Obstetrics & Gynaecology. 2009.№ 116. Р. 743-747.
7. Geoghegan J., Daniels J.P., Moore P.A., Thompson P.J.,Khan K.S., Gülmezoglu A.M. Cell salvage at caesarean section:the need for an evidence-based approach // Br. J. Obstet. Gynaecol.– 2009. Vol. 116, № 6. Р. 743-747.
8. Liumbruno G.M., Liumbruno C., Rafanelli D. Intraoperativecell salvage in obstetrics: is it a real therapeutic option?// Transfusion. 2011. Vol.51, №10. Р. 2244-2454.
9. Liumbruno G.M., Liumbruno C., Rafanelli D. Autologousblood in obstetrics: where are we going now? // BloodTransfus. 2012. № 10. Р. 125-147.
10. Liumbruno G.M., Meschini A., Liumbruno C., RafanelliD. The introduction of intra-operative cell salvage in obstetricclinical practice: a review of the available evidence // Eur. J.Obstet. Gynecol. Reprod. Biol. 2011. № 159. Р. 19-25.
11. Louage S., Van de Velde M. Cell salvage in obstеtricanesthesia // Acta Anaesthesiol. Belg. 2010. Vol. 61,№ 1. Р. 13-24.
12. Ralph C.J., Sullivan I., Faulds J. Intraoperative cellsalvaged blood as part of a blood conservation strategy inCaesarean section: is fetal red cell contamination important?// Br. J. Anaesth. 2011. № 107. Р. 404-408.
13. Surendran S.K., Allard S., Regan. Royal College of Obstetriciansand Gynaecologists (RCOG). The management of womenwith red cell antibodies during pregnancy. Royal College of Obstetriciansand Gynaecologists (RCOG); London: 2014. P. 5-15.
14. Sullivan I, Faulds J, Ralph C. Contamination of salvagedmaternal blood by amniotic fluid and fetal red cellsduring elective caesarean section // Br. J. Anaesth. 2008.№ 101. Р. 225-229.
15. Wise V.C. Challenges of major obstetric haemorrhage// Best Pract. Res. Clin. Obstet. Gynaecol. 2010.№ 24. Р. 353-365.

This article presents a case of disseminated lesion of the pulmonary tissue, revealed at the last stage
of the disease in a patient with pancreatic cancer.

1. Zhukova N.V., Kilessa V.V., Zakharova M.A.Disseminated pulmonary lesion in systemic connectivetissue diseases // Kryms’kiy therapeutichniy journal. -2013. № 1. P.119-1242. Zaitsev A.A., Antipushina D.N., Sivokozov I.V.,Chernov S.A. Diagnosis and treatment of patients withsarcoidosis in the multiprofile military hospital // Voen.-med. journ. 2012. Vol. 333, № 9. P. 35-40.
3. Il’kovich M.M. Disseminated pulmonary disease.M.: GEOTAR Media, 2011. 470 p.
4. Liskina I.V., Sil’chenko V.P., Irkin I.V., Zagaba L.M.Diffuse parenchymatous lung disease: lung biopsy opportunityin verify the diagnosis, determining the treatmentstrategy and prognosis // Ukrainsky pulmonologіchnymagazine. 2008. № 4. P. 43-465. Sivokozov I.V., Shmelev E.I., Lovachyova O.V. Difficultiesof differential diagnosis of disseminated processesin the lungs // Medical Council. 2013. № 11.P. 58-616. Shal’min A.S., Raznatovskaya E.N. Syndromeof pulmonary dissemination //Український журналекстремальної медицини імені Г.О.Можаєва.2012. Vol. 13, № 1. P. 93-96.
7. Mukherjee S., Van Pittus D. G., Spiteri M. Diffuseparenchymal lung disease: a practical overview. Is alung biopsy necessary for management? // Breathe. —2008. Vol. 4, № 3. P. 233-239.

The article presents the main stages of the dialysis service of the Krasnoyarsk Region. Here are described the
peculiarities of the first sessions of hemodialysis. . It is shown how a great way has passed the dialysis service.